← All trials
NCT05292976
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2022
- Primary completion
- Oct 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Mar 23, 2022
- Last posted
- May 20, 2022
- Enrollment
- 0
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Aurobindo PharmaLead sponsor
- Aurobindo PharmaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.